+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Polycystic Kidney Disease - Pipeline Review, H2 2019

  • ID: 4901366
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 122 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Angion Biomedica Corp
  • DiscoveryBiomed Inc
  • Genzyme Corp
  • Goldfinch Biopharma Inc
  • Ipsen SA
  • ManRos Therapeutics
  • MORE
Polycystic Kidney Disease - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Kidney Disease - Pipeline Review, H2 2019, provides an overview of the Polycystic Kidney Disease (Genetic Disorders) pipeline landscape.

Polycystic kidney disease (PKD) is a disorder in which clusters of cysts develop primarily within kidneys. Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Polycystic Kidney Disease - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Polycystic Kidney Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polycystic Kidney Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Polycystic Kidney Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 3, 2, 10 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Polycystic Kidney Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Polycystic Kidney Disease (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Polycystic Kidney Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Polycystic Kidney Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Polycystic Kidney Disease (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Polycystic Kidney Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Angion Biomedica Corp
  • DiscoveryBiomed Inc
  • Genzyme Corp
  • Goldfinch Biopharma Inc
  • Ipsen SA
  • ManRos Therapeutics
  • MORE
Introduction
Report Coverage
Polycystic Kidney Disease - Overview
Polycystic Kidney Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Polycystic Kidney Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Polycystic Kidney Disease - Companies Involved in Therapeutics Development
Angion Biomedica Corp
Bristol-Myers Squibb Co
DiscoveryBiomed Inc
Eloxx Pharmaceuticals Inc
Genzyme Corp
GLG Pharma SA
Goldfinch Biopharma Inc
IC-MedTech Inc
Ipsen SA
Kadmon Corp LLC
ManRos Therapeutics
Mironid Ltd
NovaTarg Therapeutics Inc
Palladio Biosciences Inc
Reata Pharmaceuticals Inc
Regulus Therapeutics Inc
XORTX Therapeutics Inc
Polycystic Kidney Disease - Drug Profiles
Polycystic Kidney Disease - Dormant Projects
Polycystic Kidney Disease - Discontinued Products
Polycystic Kidney Disease - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Polycystic Kidney Disease, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Polycystic Kidney Disease - Pipeline by Angion Biomedica Corp, H2 2019
Polycystic Kidney Disease - Pipeline by Bristol-Myers Squibb Co, H2 2019
Polycystic Kidney Disease - Pipeline by DiscoveryBiomed Inc, H2 2019
Polycystic Kidney Disease - Pipeline by Eloxx Pharmaceuticals Inc, H2 2019
Polycystic Kidney Disease - Pipeline by Genzyme Corp, H2 2019
Polycystic Kidney Disease - Pipeline by GLG Pharma SA, H2 2019
Polycystic Kidney Disease - Pipeline by Goldfinch Biopharma Inc, H2 2019
Polycystic Kidney Disease - Pipeline by IC-MedTech Inc, H2 2019
Polycystic Kidney Disease - Pipeline by Ipsen SA, H2 2019
Polycystic Kidney Disease - Pipeline by Kadmon Corp LLC, H2 2019
Polycystic Kidney Disease - Pipeline by ManRos Therapeutics, H2 2019
Polycystic Kidney Disease - Pipeline by Mironid Ltd, H2 2019
Polycystic Kidney Disease - Pipeline by NovaTarg Therapeutics Inc, H2 2019
Polycystic Kidney Disease - Pipeline by Palladio Biosciences Inc, H2 2019
Polycystic Kidney Disease - Pipeline by Reata Pharmaceuticals Inc, H2 2019
Polycystic Kidney Disease - Pipeline by Regulus Therapeutics Inc, H2 2019
Polycystic Kidney Disease - Pipeline by XORTX Therapeutics Inc, H2 2019
Polycystic Kidney Disease - Dormant Projects, H2 2019
Polycystic Kidney Disease - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Polycystic Kidney Disease, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Angion Biomedica Corp
  • Bristol-Myers Squibb Co
  • DiscoveryBiomed Inc
  • Eloxx Pharmaceuticals Inc
  • Genzyme Corp
  • GLG Pharma SA
  • Goldfinch Biopharma Inc
  • IC-MedTech Inc
  • Ipsen SA
  • Kadmon Corp LLC
  • ManRos Therapeutics
  • Mironid Ltd
  • NovaTarg Therapeutics Inc
  • Palladio Biosciences Inc
  • Reata Pharmaceuticals Inc
  • Regulus Therapeutics Inc
  • XORTX Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll